We have observed
3 EP applications
David Graham Read
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after January 31, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
ENHANCED GROWTH INHIBITION OF OSTEOSARCOMA BY CYTOTOXIC POLYMERIZED LIPOSOMAL NANOPARTICLES TARGETING THE ALCAM CELL SURFACE RECEPTOR
FLUID COLLECTION AND EXPULSION APPARATUS